Breaking News: FDA Approves Zoryve (roflumilast) for the Treatment of Seborrheic Dermatitis

Approvals

By National Eczema Association

Published On: Dec 15, 2023

Last Updated On: Jan 2, 2024

Today the eczema community is one step closer to having a new treatment option. The U.S. Food and Drug Administration (FDA) has approved Zoryve foam 0.3%, from manufacturer Arcutis Biotherapeutics, for the treatment of seborrheic dermatitis in patients 9 years of age and older. Zoryve is the first drug approved for seborrheic dermatitis with a new mechanism of action in over two decades.

Zoryve foam 0.3% is a once-daily topical, selective PDE4 inhibitor, which is indicated for the treatment of seborrheic dermatitis in individuals 9 years of age and older. The steroid-free foam can be used chronically anywhere on the body, including hair-bearing areas of the body such as the scalp, face and trunk which can be especially susceptible to seborrheic dermatitis. 

It’s important to talk to your doctor about how seborrheic dermatitis affects your skin and other aspects of your life. Together, you and your healthcare provider can determine if Zoryve is an appropriate treatment option.

Visit our New Prescription Treatment hub to find out about other new therapies as they are available.

Get the latest eczema news delivered to your inbox.